Genpact vs Paychex
G and PAYX side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How G and PAYX compare
Paychex is the larger company, worth 6.0 times as much as Genpact ($39.9B against $6.7B).
On earnings, Genpact is cheaper: it trades at 11.8× trailing earnings, against 22.2× for Paychex.
Paychex grew revenue faster over the last twelve months (14.0% versus 6.5% for Genpact).
Paychex keeps more of each dollar of sales as profit, with a net margin of 27.4% compared with 11.1% at Genpact.
Both pay dividends: Genpact yields 1.4% and Paychex 5.1%.
Genpact scores higher on the StockData Score (21 against 20 for Paychex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | G | PAYX |
|---|---|---|
| Size and price | ||
| Market cap | $6.7B | $39.9B |
| Share price | $39.62 | $112.12 |
| Change, 1 year | 4.6% | −4.5% |
| Change, 5 years | −21.6% | −10.0% |
| Beta (5Y) | 0.66 | 0.76 |
| Employees | 147K | 18K |
| StockData Score | ||
| Total score | 21 (better) | 20 |
| Valuation score | 5 (better) | 4 |
| Growth score | 3 | 3 |
| Performance score | 6 (better) | 3 |
| Health score | 4 | 4 |
| Dividend score | 3 | 6 (better) |
| Valuation | ||
| P/E | 11.8× (better) | 22.2× |
| P/S | 1.3× (better) | 6.0× |
| P/B | 2.6× (better) | 10.8× |
| EV/EBITDA | 9.4× (better) | 14.4× |
| P/FCF | 11.6× (better) | 19.8× |
| PEG | 0.63 (better) | 5.08 |
| FCF yield | 8.6% (better) | 5.1% |
| Fair value | $56.35 | $125.36 |
| Margin of safety | 29.7% (better) | 10.6% |
| Growth | ||
| Revenue growth (TTM) | 6.5% | 14.0% (better) |
| Revenue growth, 5Y average | 6.5% | 9.9% (better) |
| Net income growth (TTM) | 8.2% | 11.9% (better) |
| EPS growth (TTM) | 12.0% | 13.3% (better) |
| EPS growth, 5Y average | 14.8% (better) | 10.0% |
| Profitability | ||
| Gross margin | 36.5% | 74.4% (better) |
| Operating margin | 14.8% | 39.2% (better) |
| Net margin | 11.1% | 27.4% (better) |
| FCF margin | 10.9% | 30.5% (better) |
| Return on equity | 22.4% | 47.1% (better) |
| Return on invested capital | 18.3% | 26.9% (better) |
| Financial health | ||
| Debt / equity | 0.45 (better) | 1.23 |
| Net debt / EBITDA | 0.85 (better) | 1.20 |
| Interest coverage | – | 9.7× |
| Current ratio | 2.00 (better) | 1.28 |
| Altman Z-score | 3.50 (better) | 3.26 |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.4% | 5.1% (better) |
| Payout ratio | 20.9% | 90.0% |
| Years of dividend growth | 6 | 15 (better) |
| Dividend growth, 5Y average | 11.8% | 11.9% (better) |
| Buyback yield | – | 1.1% |
| Shareholder yield | 1.4% | 6.2% (better) |
| Ownership | ||
| Held by institutions | 107% | 83.3% |
| Held by insiders | 35.7% | 10.1% |
| Insider net buying, 12 months | −$8.1M | −$3.6M (better) |
| Superinvestors holding | 1 | 2 (better) |
| Short interest, % of float | 10.2% | 5.9% |
Go deeper
- G stock overview
- G income statement
- G valuation and score
- PAYX stock overview
- PAYX income statement
- PAYX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.